Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 8/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.49 |
| ▸ | USP10 | Q14694 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923646 | 0.85 | USP10 (0.46) | USP10RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL1923448 | 0.82 | USP10 (0.45) | USP10NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL1923440 | 0.81 | USP10 (0.42) | USP10NPC1RAB9AMAPT | |
| SCHEMBL1924395 | 0.80 | RAB9A (0.47) | USP10NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL1923836 | 0.80 | MEN1 (0.50) | USP10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1924088 | 0.79 | PTGDR2 (0.47) | USP10MAPTKDM4E | |
| SCHEMBL1923602 | 0.79 | CPT2 (0.55) | MAPTSMN1; SMN2 | |
| SCHEMBL1923603 | 0.78 | USP10 (0.53) | USP10NPC1RAB9AMAPTTSHR | |
| SCHEMBL1924745 | 0.78 | EGFR (0.47) | USP10RAB9AMAPTTSHRSMN1; SMN2 | |
| SCHEMBL1923793 | 0.77 | USP10 (0.45) | USP10RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064185-B1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2011-06-08 | — | — | EP | claimed |
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-01 | — | — | US | claimed |
| CN-101522630-A | 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INT (ES) | 2009-09-02 | — | — | CN | claimed |
| EP-2064185-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | Ferrer Internacional, S.A. (ES) | 2009-06-03 | — | — | EP | claimed |
| WO-2008017710-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL S.A. (ES) | 2008-02-14 | — | — | WO | claimed |
| EP-1886996-A1 | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-13 | — | — | EP | claimed |
| EP-2064185-B1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2011-06-08 | — | — | EP | disclosed |
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| CN-101522630-A | 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INT (ES) | 2009-09-02 | — | — | CN | disclosed |
| EP-1886996-A1 | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | GABRA1, GABRA4, GABRA2 | NTRK1 358/4885NTRK3 1668/4885USP10 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.